Oncology Institute (NASDAQ:STLN) Stock Keeps “Buy” Rating at B. Riley Financial

B. Riley Financial restated their buy rating on shares of Oncology Institute (NASDAQ:STLN) in a research note released on Friday,Benzinga reports. They currently have a $10.00 price target on the stock, down from their prior price target of $11.00.

Other equities analysts have also issued reports about the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Oncology Institute in a research note on Tuesday. Needham & Company LLC boosted their price objective on shares of Oncology Institute from $7.00 to $9.00 and gave the stock a “buy” rating in a research report on Wednesday, October 14th. Finally, BTIG Research boosted their price objective on shares of Oncology Institute from $9.00 to $10.00 and gave the stock a “buy” rating in a research report on Friday. Four equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $9.75.

Oncology Institute Price Performance

Shares of NASDAQ:STLN traded down $3.08 on Friday, hitting $3.62. 23,895,218 shares of the company’s stock were exchanged, compared to its average volume of 1,268,476. Oncology Institute has a 1-year low of $2.32 and a 1-year high of $7.13. The stock has a market capitalization of $357.80 million, a P/E ratio of -12.48 and a beta of 0.44. The stock’s 50-day moving average is $6.43.

Oncology Institute (NASDAQ:STLN) last issued its earnings results on Thursday, November 5th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.06). The firm had revenue of $169.77 million during the quarter. Equities analysts predict that Oncology Institute will post -0.21 EPS for the current fiscal year.

Insider Transactions at Oncology Institute

In related news, Director Brad Hively sold 298,853 shares of the company’s stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $6.51, for a total value of $1,945,533.03. Following the completion of the sale, the director directly owned 411,976 shares of the company’s stock, valued at $2,681,963.76. This represents a 42.04% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, major shareholder Jorey Chernett purchased 12,000 shares of the company’s stock in a transaction that occurred on Friday, August 14th. The shares were purchased at an average price of $6.54 per share, for a total transaction of $78,480.00. Following the purchase, the insider directly owned 10,660,858 shares in the company, valued at $69,722,011.32. The trade was a 0.11% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. 4.40% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Bank of New York Mellon Corp acquired a new stake in shares of Oncology Institute in the second quarter valued at approximately $961,000. State Street Corp purchased a new position in shares of Oncology Institute during the second quarter worth approximately $8,432,000. Bank of America Corp DE acquired a new position in shares of Oncology Institute in the 2nd quarter valued at $2,129,000. Arrowstreet Capital Limited Partnership increased its holdings in shares of Oncology Institute by 169.3% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 419,423 shares of the company’s stock valued at $1,288,000 after acquiring an additional 263,699 shares during the period. Finally, Cetera Investment Advisers increased its holdings in shares of Oncology Institute by 427.8% in the 1st quarter. Cetera Investment Advisers now owns 128,195 shares of the company’s stock valued at $394,000 after acquiring an additional 103,908 shares during the period. Institutional investors and hedge funds own 36.86% of the company’s stock.

Oncology Institute News Roundup

Here are the key news stories impacting Oncology Institute this week:

• Positive Sentiment: BTIG Research raised its price target to $10 from $9 and maintained a “buy” rating, indicating substantial potential upside in its view. TickerReport article
• Neutral Sentiment: B. Riley reaffirmed its “buy” rating but lowered its target to $10 from $11, signaling continued optimism alongside a more cautious valuation. B. Riley rating
• Negative Sentiment: For the third quarter, the company reported a loss of $0.13 per share, worse than the $0.07 loss analysts expected, although the loss narrowed from $0.14 a year earlier. Revenue was $169.77 million and beat estimates. Quarterly results coverage
• Negative Sentiment: Full-year 2026 revenue guidance of $650 million–$660 million came in below the $665 million consensus estimate, raising concern about the company’s growth outlook. Company results and guidance

Oncology Institute Company Profile

The Oncology Institute is a value-based oncology care company focused on delivering comprehensive cancer treatment and related services through community-based care settings. Its model is designed to support patients throughout the cancer-care journey while coordinating treatment among oncologists, primary-care providers, specialists and other healthcare professionals.

The company provides medical oncology and hematology services, cancer screening and diagnosis, treatment planning, chemotherapy and other infusion therapies, supportive care, survivorship services and care-management programs.